In a nutshell In this analysis, the European Organization for Research and Treatment of Cancer (EORTC) and the International Society of Geriatric Oncology (SIOG) updated recommendations for treating elderly patients with non-small-cell lung cancer (NSCLC). Some background The average age of patients diagnosed with NSCLC is 71 years old. This is...
Read More
In a nutshell This review compared the combination of cetuximab (Erbitux) and chemotherapy to chemotherapy alone in treating advanced non-small cell lung cancer (NSCLC). The review found that combining cetuximab with chemotherapy is more effective than chemotherapy alone. It also found that although there were more adverse effects with the...
Read More
In a nutshell This review aimed to assess the efficacy and safety of the new anticancer drug dacomitinib in comparison to current drug erlotinib. Both drugs are used to treat advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. The study found that dacomitinib was marginally more effective than erlotinib in specific EGFR-mutant-NSCLC. Some...
Read MoreIn a nutshell This study compared the effectiveness and safety of nivolumab (Opdivo) and docetaxel (Taxotere) for the treatment of advanced squamous-cell non-small-cell lung cancer (NSCLC). The study concluded that nivolumab is more effective and safer than docetaxel for this type of cancer. Some background PD-L1 is a protein that...
Read More
In a nutshell This review was conducted in an effort to update current guidelines for the prevention of nausea and vomiting in patients receiving chemotherapy. According to this update by the American Society of Clinical Oncology, all patients who receive highly emetogenic chemotherapies (treatments known to cause nausea and vomiting) should be...
Read More
Stating the obvious: cancer takes an enormous toll on the sick individual and their family. Being stretched financially and every other way-emotionally, physically, spiritually and everything in between-may make the idea of a vacation a low priority. Yet downtime is important. But what if the vacation were free? There are organizations that have made it...
Read More
In a nutshell This trial assessed the effectiveness of combining a TG4010, a type of immunotherapy, with chemotherapy for non-small-cell lung cancer. It also examined whether TG4010 was more effective in patients with a low level of certain immune cells, called triple positive activated lymphocytes (TrPAL). The study concluded that TG4010 was...
Read More
In a nutshell This study aimed to determine the efficacy of a combination of the anticancer drugs afatinib (Gilotrif) and paclitaxel (Taxol) to treat non-small cell lung cancer (NSCLC), compared to chemotherapy alone. The study found that a combination of these drugs significantly improved progression free survival (PFS, time from treatment until...
Read More
In a nutshell This study compared weak opioids and low-dose morphine in providing pain relief for moderate cancer pain. Researchers concluded that low-dose morphine is more suitable as pain management for moderate cancer pain than weaker pain relievers. Some background The guidelines for cancer pain relief developed by the World Health...
Read More
In a nutshell This study aimed to see whether combining postoperative radiotherapy (PORT) with adjuvant (following surgery) chemotherapy would be effective in patients with N2 (spread to lymph nodes around the lung) non-small-cell lung cancer (NSCLC). The researchers concluded that using PORT in combination with chemotherapy increased overall survival...
Read More
In a nutshell This study compared the efficacy of antitumor drugs nivolumab (Opdivo) and docetaxel (Taxotere) in the treatment of advanced non-small-cell lung cancer (NSCLC). The study concluded that nivolumab has better activity in advanced nonsquamous NSCLC which express the ligand PD-L1 and has a safer toxicity profile overall than docetaxel. Some...
Read More
In a nutshell This study aimed to determine the safety and efficacy of a combination of the anticancer drugs afatinib (Gilotrif) and nimotuzumab (Theraloc) to treat kinase inhibitor resistant EGFR-mutant-NSCLC. The study found that a combination of these drugs had encouraging potential and an acceptable safety profile. Some background A mutation...
Read More
